TRASTUZUMAB AND PERTUZUMAB COMBINATION THERAPY ACTIVATES COMPLEMENT-DEPENDENT CYTOTOXICITY AND PHAGOCYTOSIS AGAINST HER2+BREAST CANCER

被引：0
|
作者：
Tsao, Li-Chung [1 ]
Hartman, Zachary [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
617
引用
收藏
页码：A647 / A647
页数：1
相关论文
共 50 条
  • [41] HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer
    Hamilton, Erika P.
    Martin, Miguel
    O'Sullivan, Ciara Catherine
    Curigliano, Giuseppe
    Sohn, Joohyuk
    Tsurutani, Junji
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] COST COMPARISON BETWEEN THE USE OF PERTUZUMAB-TRASTUZUMAB SC AND IV FORMULATIONS TO TREAT HER2+BREAST CANCER PATIENTS IN ALGERIA
    Hedibel, M.
    Bouchebout, H. A.
    Ghomari, I
    Al Assaad, A.
    Guendouzi, S.
    VALUE IN HEALTH, 2024, 27 (12) : S111 - S111
  • [43] Adjuvant trastuzumab and vinorelbine for early-stage HER2+breast cancer
    McLaughlin, Shannon
    Nakajima, Erika
    Bar, Yael
    Hutchinson, Jennifer A. A.
    Shin, Jennifer
    Moy, Beverly
    Isakoff, Steven J. J.
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura M. M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [44] Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+Breast Cancer
    Song, Patrick N.
    Mansur, Ameer
    Lu, Yun
    Della Manna, Deborah
    Burns, Andrew
    Samuel, Sharon
    Heinzman, Katherine
    Lapi, Suzanne E.
    Yang, Eddy S.
    Sorace, Anna G.
    CANCERS, 2022, 14 (04)
  • [45] Inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+breast cancer
    Miller, K. D.
    Steding, C. E.
    Prasad, N.
    Rojas, L. A.
    Herbert, B-S
    CANCER RESEARCH, 2012, 72
  • [46] Phase II study of gemcitabine, trastuzumab, and pertuzumab in the treatment of metastatic HER2-positive breast cancer after prior trastuzumab/pertuzumab- or pertuzumab-based therapy
    Iyengar, N. M.
    Argolo, D.
    Smyth, L.
    Chen, M. F.
    Hudis, C. A.
    Dang, C. T.
    CANCER RESEARCH, 2016, 76
  • [47] Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+Breast Cancer
    Castro-Guijarro, Ana Carla
    Sanchez, Angel Matias
    Flamini, Marina Ines
    Vogel, Christoph F. A.
    CANCERS, 2023, 15 (17)
  • [48] Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+breast cancer
    Iwata, H.
    Yamamoto, N.
    Masuda, N.
    Bando, H.
    Kuroi, K.
    Ohno, S.
    Kasai, H.
    Morita, S.
    Sakurai, T.
    Toi, M.
    BREAST, 2015, 24 : S95 - S95
  • [49] The trastuzumab era: current and upcoming targeted HER2+breast cancer therapies
    Kreutzfeldt, Jordyn
    Rozeboom, Brett
    Dey, Nandini
    De, Pradip
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (04): : 1045 - 1067
  • [50] Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is dependent on HER2/CEP17 ratio in HER2-positive breast cancer
    Jung, S.
    Jeon, C. W.
    Choi, J.
    Hyun, D.
    Lee, H.
    Kwon, K.
    Yoon, H.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S59 - S59
12345